What is the share price of Indoco Remedies Ltd (INDOCO) today?
The share price of INDOCO as on 30th June 2025 is ₹317.60. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Indoco Remedies Ltd (INDOCO) share?
The past returns of Indoco Remedies Ltd (INDOCO) share are- Past 1 week: 5.88%
- Past 1 month: 19.60%
- Past 3 months: 36.37%
- Past 6 months: -3.70%
- Past 1 year: -4.22%
- Past 3 years: -13.47%
- Past 5 years: 55.84%
What are the peers or stocks similar to Indoco Remedies Ltd (INDOCO)?
The peers or stocks similar to Indoco Remedies Ltd (INDOCO) include:What is the dividend yield % of Indoco Remedies Ltd (INDOCO) share?
The current dividend yield of Indoco Remedies Ltd (INDOCO) is 0.06.What is the market cap of Indoco Remedies Ltd (INDOCO) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Indoco Remedies Ltd (INDOCO) is ₹2927.04 Cr as of 30th June 2025.What is the 52 week high and low of Indoco Remedies Ltd (INDOCO) share?
The 52-week high of Indoco Remedies Ltd (INDOCO) is ₹387.55 and the 52-week low is ₹190.What is the PE and PB ratio of Indoco Remedies Ltd (INDOCO) stock?
The P/E (price-to-earnings) ratio of Indoco Remedies Ltd (INDOCO) is -39.69. The P/B (price-to-book) ratio is 2.64.Which sector does Indoco Remedies Ltd (INDOCO) belong to?
Indoco Remedies Ltd (INDOCO) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy Indoco Remedies Ltd (INDOCO) shares?
You can directly buy Indoco Remedies Ltd (INDOCO) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Indoco Remedies Ltd
INDOCO Share Price
317.605.27% (+15.90)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
INDOCO Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
BadThe stock is overpriced and in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
INDOCO Performance & Key Metrics
INDOCO Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -39.70 | 2.64 | 0.06% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 36.56 | 6.60 | 0.83% |
0%
Analysts have suggested that investors can buy this stock
from 4 analysts
Price Upside
Earnings Growth
Rev. Growth
INDOCO Company Profile
Indoco Remedies Limited is engaged in the manufacture of pharmaceutical products. The Company primarily manufactures and markets Formulations (Finished Dosage Forms) and Active Pharmaceutical Ingredients (APIs).
SUNPHARMA
PE Ratio
36.79
36.79
1Y Return
10.24%
10.24%
Buy Reco %
87.88
87.88
CIPLA
PE Ratio
23.07
23.07
1Y Return
1.81%
1.81%
Buy Reco %
74.19
74.19
TORNTPHARM
PE Ratio
60.36
60.36
1Y Return
22.54%
22.54%
Buy Reco %
75.00
75.00
DRREDDY
PE Ratio
18.88
18.88
1Y Return
0.99%
0.99%
Buy Reco %
55.17
55.17
ZYDUSLIFE
PE Ratio
22.01
22.01
1Y Return
7.25%
7.25%
Buy Reco %
46.43
46.43
INDOCO Sentiment Analysis
INDOCO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly
INDOCO Stock Summary · May 2025
The company is currently grappling with significant operational challenges and financial pressures, primarily stemming from investments in a new subsidiary targeting the over-the-counter market, which has yet to yield substantial sales. Despite these hurdles, there is cautious optimism regarding future growth, particularly with expectations of improved performance from the sterile facility and new product launches that could drive market recovery. The strategic shift towards online retail and enhanced brand development is aimed at stabilizing sales dynamics, while ongoing cost management efforts are critical to navigating rising fixed costs. Additionally, the company is focused on optimizing its capital expenditures and maintaining a robust R&D investment to leverage market opportunities, even as it addresses its substantial debt burden. Overall, management remains committed to improving operational efficiency and regaining market share amidst a challenging landscape.
INDOCO Stock Growth Drivers
INDOCO Stock Growth Drivers
7Strong Sales Performance
Indoco Remedies Limited has reported a significant increase in its international business revenues, with a
Successful Audits and Regulatory Progress
The company successfully passed an audit by the European Medicines Agency (EMA) for its Plant
INDOCO Stock Challenges
INDOCO Stock Challenges
6Financial Performance Decline
Indoco Remedies has reported a significant decline in financial performance, with standalone net revenues for
Operational Challenges and Manufacturing Issues
The company has faced significant operational challenges, including planned shutdowns at several manufacturing sites, which
INDOCO Forecast
INDOCO Forecasts
Price
Revenue
Earnings
INDOCO Share Price Forecast
INDOCO Share Price Forecast
2025
Current
₹317.60
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹317.60
Baseline
Forecast for Jun 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
INDOCO Company Revenue Forecast
INDOCO Company Revenue Forecast
2025
Current
₹1.67
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
2025
Current
₹1.67
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹ Thousand cr.
INDOCO Stock EPS (Earnings Per Share) Forecast
INDOCO Stock EPS (Earnings Per Share) Forecast
2025
Current
₹-8.46
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
2025
Current
₹-8.46
Baseline
Forecast for Mar 2026
High
₹—
Median
₹—
Low
₹—
All values in ₹
INDOCO
INDOCO
Income
Balance Sheet
Cash Flow
Annual Normal View
INDOCO Income Statement
INDOCO Income Statement
Annual Normal View
| Financial Year | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,078.73 | 1,046.63 | 974.60 | 1,109.02 | 1,244.65 | 1,543.08 | 1,670.95 | 1,846.87 | 1,671.36 | 1,671.36 | ||||||||||
Raw Materials | 362.83 | 344.53 | 306.93 | 338.48 | 366.23 | 483.09 | 514.74 | 600.67 | 1,565.66 | 1,565.64 | ||||||||||
| Power & Fuel Cost | 23.12 | 26.62 | 28.49 | 34.75 | 36.89 | 42.78 | 50.61 | 56.00 | ||||||||||||
| Employee Cost | 216.67 | 220.91 | 231.66 | 256.51 | 274.02 | 296.28 | 322.58 | 361.93 | ||||||||||||
| Selling & Administrative Expenses | 255.89 | 246.31 | 241.21 | 287.26 | 257.82 | 292.67 | 339.43 | 414.96 | ||||||||||||
| Operating & Other expenses | 59.79 | 68.64 | 83.51 | 66.38 | 82.30 | 98.59 | 155.15 | 147.62 | ||||||||||||
EBITDA | 160.43 | 139.62 | 82.80 | 125.64 | 227.39 | 329.67 | 288.44 | 265.69 | 105.70 | 105.72 | ||||||||||
| Depreciation/Amortization | 63.28 | 67.71 | 71.57 | 70.82 | 73.13 | 78.96 | 70.61 | 91.87 | 113.84 | 113.84 | ||||||||||
| PBIT | 97.15 | 71.91 | 11.23 | 54.82 | 154.26 | 250.71 | 217.83 | 173.82 | -8.14 | -8.12 | ||||||||||
| Interest & Other Items | 6.21 | 23.51 | 20.54 | 26.25 | 22.26 | 14.14 | 25.03 | 38.02 | 66.23 | 66.23 | ||||||||||
| PBT | 90.94 | 48.40 | -9.31 | 28.57 | 132.00 | 236.57 | 192.80 | 135.80 | -74.37 | -74.35 | ||||||||||
| Taxes & Other Items | 13.87 | 7.23 | -6.41 | 4.46 | 38.95 | 81.77 | 50.55 | 37.33 | -0.63 | -0.62 | ||||||||||
| Net Income | 77.07 | 41.17 | -2.90 | 24.11 | 93.05 | 154.80 | 142.25 | 98.47 | -73.74 | -73.73 | ||||||||||
| EPS | 8.36 | 4.47 | -0.31 | 2.62 | 10.10 | 16.80 | 15.44 | 10.68 | -8.46 | -8.00 | ||||||||||
| DPS | 1.60 | 1.00 | 0.30 | 0.30 | 1.50 | 2.25 | 2.25 | 1.50 | 0.20 | 1.50 | ||||||||||
| Payout ratio | 0.19 | 0.22 | — | 0.11 | 0.15 | 0.13 | 0.15 | 0.14 | — | -0.19 |
INDOCO Company Updates
FY 2025FY 2025
Investor Presentation
Oct 24PDF
INDOCO Stock Peers
INDOCO Past Performance & Peer Comparison
INDOCO Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation-basic on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation-basic on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Indoco Remedies Ltd | -39.69 | 2.64 | 0.06% |
| Sun Pharmaceutical Industries Ltd | 36.79 | 5.99 | 0.95% |
| Cipla Ltd | 23.07 | 3.89 | 1.06% |
| Torrent Pharmaceuticals Ltd | 60.36 | 16.82 | 0.94% |
INDOCO Stock Price Comparison
Compare INDOCO with any stock or ETFCompare INDOCO with any stock or ETF
INDOCO
INDOCO Holdings
INDOCO Shareholdings
INDOCO Promoter Holdings Trend
INDOCO Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
INDOCO Institutional Holdings Trend
INDOCO Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
INDOCO Shareholding Pattern
INDOCO Shareholding Pattern
INDOCO Shareholding History
INDOCO Shareholding History
Foreign Institutions
Mutual Funds Invested in INDOCO
Mutual Funds Invested in INDOCO
No mutual funds holding trends are available
Top 5 Mutual Funds holding Indoco Remedies Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 0.5624% | Percentage of the fund’s portfolio invested in the stock 0.09% | Change in the portfolio weight of the stock over the last 3 months 0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 161/236 (-77) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4797% | Percentage of the fund’s portfolio invested in the stock 0.81% | Change in the portfolio weight of the stock over the last 3 months 0.10% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 48/61 (-3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.4112% | Percentage of the fund’s portfolio invested in the stock 0.51% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 61/68 (-2) |
Compare 3-month MF holding change on Screener
smallcases containing INDOCO stock
smallcases containing INDOCO stock
Looks like this stock is not in any smallcase yet.
INDOCO Events
INDOCO Events
INDOCO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
INDOCO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.07%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.66 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
INDOCO Dividend Trend
No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year
INDOCO has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation
Current dividend yield is 0.07%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹0.66 every year
INDOCO Upcoming Dividends
INDOCO Upcoming Dividends
No upcoming dividends are available
INDOCO Past Dividends
INDOCO Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2024
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 19, 2024
Cash Dividend
Ex DateEx DateSep 18, 2023
Final
Final | Div/Share: ₹2.25
Dividend/Share
₹2.25
Ex DateEx Date
Sep 18, 2023
Cash Dividend
Ex DateEx DateSep 14, 2022
Special
Special | Div/Share: ₹0.75
Dividend/Share
₹0.75
Ex DateEx Date
Sep 14, 2022
Cash Dividend
Ex DateEx DateSep 14, 2022
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 14, 2022
Cash Dividend
Ex DateEx DateSep 17, 2021
Final
Final | Div/Share: ₹1.50
Dividend/Share
₹1.50
Ex DateEx Date
Sep 17, 2021
INDOCO Stock News & Opinions
INDOCO Stock News & Opinions
Articles & Videos
Corporate
Indoco Remedies receives USFDA final approval for Allopurinol Tablets
Indoco Remedies announced final approval of Allopurinol Tablets USP, 200 mg through Company's Abbreviated New Drug Application (ANDA) for Allopurinol Tablets USP to market a generic equivalent to the reference listed drug (RLD), ZYLOPRIM 200 mg of Casper Pharma LLC from USFDA.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Indoco Remedies gains after receiving USFDA nod for Allopurinol drug
Allopurinol is used to prevent or lower high uric acid levels in the blood. It is also used to prevent or lower excess uric acid levels caused by cancer medicines or in patients with kidney stones. The drug is the generic equivalent of the reference listed drug (RLD), Zyloprim, marketed by Casper Pharma LLC. Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). The pharmaceutical company reported a standalone net loss of Rs 10.23 crore in Q3 FY25 as against a net profit of Rs 20.01 crore posted in Q3 FY24. Revenue from operations stood at Rs 364.91 crore in the third quarter of FY25, down 18.61% as against Rs 448.38 crore posted in Q3 FY24. Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Indoco Remedies reports consolidated net loss of Rs 40.39 crore in the March 2025 quarter
Net loss of Indoco Remedies reported to Rs 40.39 crore in the quarter ended March 2025 as against net profit of Rs 22.70 crore during the previous quarter ended March 2024. Sales declined 12.57% to Rs 383.89 crore in the quarter ended March 2025 as against Rs 439.08 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 73.74 crore in the year ended March 2025 as against net profit of Rs 98.47 crore during the previous year ended March 2024. Sales declined 8.22% to Rs 1641.29 crore in the year ended March 2025 as against Rs 1788.22 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales383.89439.08 -13 1641.291788.22 -8 OPM %-0.2011.13 -6.0513.66 - PBDT-16.7439.48 PL 38.48216.14 -82 PBT-45.5213.25 PL -75.36124.27 PL NP-40.3922.70 PL -73.7498.47 PL Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Board of Indoco Remedies recommends final dividend
Indoco Remedies announced that the Board of Directors of the Company at its meeting held on 22 May 2025, inter alia, have recommended the final dividend of Rs 0.2 per equity Share (i.e. 10%) , subject to the approval of the shareholders.Powered by Capital Market - Live
1 month agoCapital Market - Live
Earnings
Indoco Remedies reports standalone net loss of Rs 26.24 crore in the March 2025 quarter
Net loss of Indoco Remedies reported to Rs 26.24 crore in the quarter ended March 2025 as against net profit of Rs 37.56 crore during the previous quarter ended March 2024. Sales declined 21.62% to Rs 341.07 crore in the quarter ended March 2025 as against Rs 435.14 crore during the previous quarter ended March 2024. For the full year,net loss reported to Rs 8.73 crore in the year ended March 2025 as against net profit of Rs 116.64 crore during the previous year ended March 2024. Sales declined 15.16% to Rs 1494.78 crore in the year ended March 2025 as against Rs 1761.95 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales341.07435.14 -22 1494.781761.95 -15 OPM %1.0113.18 -8.5714.64 - PBDT-6.0250.50 PL 89.89229.67 -61 PBT-30.9026.77 PL -8.36141.69 PL NP-26.2437.56 PL -8.73116.64 PL Powered by Capital Market - Live
1 month agoCapital Market - Live
Corporate
Indoco Remedies to conduct board meeting
Indoco Remedies will hold a meeting of the Board of Directors of the Company on 22 May 2025.Powered by Capital Market - Live
1 month agoCapital Market - Live
Spotlight
Indoco Remedies Ltd leads losers in 'B' group
Premier Energies Ltd, Shiva Texyarn Ltd, Waaree Energies Ltd and Khandwala Securities Ltd are among the other losers in the BSE's 'B' group today, 22 January 2025.Indoco Remedies Ltd lost 13.90% to Rs 294.75 at 14:31 IST.The stock was the biggest loser in the BSE's 'B' group.On the BSE, 25276 shares were traded on the counter so far as against the average daily volumes of 3713 shares in the past one month.Premier Energies Ltd tumbled 11.89% to Rs 1036.15. The stock was the second biggest loser in 'B' group.On the BSE, 1.09 lakh shares were traded on the counter so far as against the average daily volumes of 87379 shares in the past one month.Shiva Texyarn Ltd crashed 11.75% to Rs 228. The stock was the third biggest loser in 'B' group.On the BSE, 8298 shares were traded on the counter so far as against the average daily volumes of 4251 shares in the past one month.Waaree Energies Ltd dropped 10.32% to Rs 2397. The stock was the fourth biggest loser in 'B' group.On the BSE, 2.17 lakh shares were traded on the counter so far as against the average daily volumes of 90579 shares in the past one month.Khandwala Securities Ltd plummeted 10.14% to Rs 28.01. The stock was the fifth biggest loser in 'B' group.On the BSE, 3530 shares were traded on the counter so far as against the average daily volumes of 5298 shares in the past one month.Powered by Capital Market - Live
5 months agoCapital Market - Live
Earnings
Indoco Remedies reports consolidated net loss of Rs 26.39 crore in the December 2024 quarter
Net loss of Indoco Remedies reported to Rs 26.39 crore in the quarter ended December 2024 as against net profit of Rs 16.30 crore during the previous quarter ended December 2023. Sales declined 12.27% to Rs 402.45 crore in the quarter ended December 2024 as against Rs 458.75 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales402.45458.75 -12 OPM %2.9913.71 - PBDT-3.2355.18 PL PBT-31.9530.83 PL NP-26.3916.30 PL Powered by Capital Market - Live
5 months agoCapital Market - Live
Corporate
Indoco Remedies allots 65,700 equity shares under ESOP
Indoco Remedies has allotted 65,700 equity shares under ESOP on 21 January 2025. With this allotment, the paid up equity share capital has increased to Rs. 18,44,95,810 (consisting of 9,22,47,905 equity shares of face value of Rs. 2 each).Powered by Capital Market - Live
5 months agoCapital Market - Live
Spotlight
Indoco Remedies slides on recording dismal Q3 numbers in FY25
Revenue from operations stood at Rs 364.91 crore in the third quarter of FY25, down 18.61% as against Rs 448.38 crore posted in Q3 FY24. The company reported a pre-tax loss of Rs 14.35 crore in Q3 FY25 as against profit before tax of Rs 35.22 crore posted in Q3 FY24. The firm recorded exceptional items of Rs 0.99 crore in the December quarter 2025. Total expenses fell 6.03% YoY to Rs 391.59 crore in Q3 FY25. The cost of materials consumed was at Rs 91.54 crore in Q3 FY25 (down 20.54% YoY), and employee benefit expenses stood at Rs 90.72 crore in Q3 FY25 (down 3.86% YoY) during the quarter. EBIDTA stood at Rs 20.10 crore in the third quarter of FY25, down 69.21% from Rs 65.30 crore posted in Q3 FY24. On a nine-month basis, the company's standalone net profit tumbled 77.85% to Rs 17.51 crore on 13.04% decrease in revenue to Rs 1,153.7 crore in 9M FY25 over 9M FY24. Aditi Panandikar, MD, Indoco Remedies, said, 'Domestic Formulation Business continued to contribute to revenue growth, while the Export Formulation Business has been impacted by supply constraints from our sites that underwent planned shutdowns for enhancement of capacities and productivity.' Indoco Remedies is engaged in the manufacturing and marketing of formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). Powered by Capital Market - Live
5 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 8.55%, vs industry avg of 10.2%
Over the last 5 years, market share decreased from 0.44% to 0.4%